SG11202112925PA - Recombinant fap binding proteins and their use - Google Patents

Recombinant fap binding proteins and their use

Info

Publication number
SG11202112925PA
SG11202112925PA SG11202112925PA SG11202112925PA SG11202112925PA SG 11202112925P A SG11202112925P A SG 11202112925PA SG 11202112925P A SG11202112925P A SG 11202112925PA SG 11202112925P A SG11202112925P A SG 11202112925PA SG 11202112925P A SG11202112925P A SG 11202112925PA
Authority
SG
Singapore
Prior art keywords
binding proteins
fap binding
recombinant fap
recombinant
proteins
Prior art date
Application number
SG11202112925PA
Inventor
Ulrike Fiedler
Clara Metz
Mischa Roland Müller
Dan Snell
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of SG11202112925PA publication Critical patent/SG11202112925PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
SG11202112925PA 2019-06-04 2020-06-03 Recombinant fap binding proteins and their use SG11202112925PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19178277 2019-06-04
PCT/EP2020/065317 WO2020245173A1 (en) 2019-06-04 2020-06-03 Recombinant fap binding proteins and their use

Publications (1)

Publication Number Publication Date
SG11202112925PA true SG11202112925PA (en) 2021-12-30

Family

ID=66857625

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112925PA SG11202112925PA (en) 2019-06-04 2020-06-03 Recombinant fap binding proteins and their use

Country Status (12)

Country Link
US (1) US20220242973A1 (en)
EP (1) EP3980045A1 (en)
JP (1) JP2022535415A (en)
KR (1) KR20220016942A (en)
CN (1) CN114269366A (en)
AU (1) AU2020286600A1 (en)
BR (1) BR112021024231A2 (en)
CA (1) CA3139164A1 (en)
IL (1) IL288610A (en)
MX (1) MX2021014601A (en)
SG (1) SG11202112925PA (en)
WO (1) WO2020245173A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021116462A1 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
AU2021267411A1 (en) 2020-05-06 2022-12-08 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
CN115943312A (en) 2020-05-07 2023-04-07 法国居里学院 Biomarker ANTXR1 of immunosuppressive fibroblast population and its use in predicting response to immunotherapy
BR112023018293A2 (en) 2021-03-09 2023-10-31 Molecular Partners Ag DARPIN-BASED MULTI-SPECIFIC T-CELL COUPLER
WO2024003393A1 (en) * 2022-06-30 2024-01-04 Navigo Proteins Gmbh Fusion proteins with half life extending domains
WO2024074706A1 (en) 2022-10-07 2024-04-11 Universität Zürich Paracrine adenoviral delivery of biomolecules

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
KR20140032356A (en) 2010-11-26 2014-03-14 몰리큘라 파트너스 아게 Improved n-terminal capping modules for designed ankyrin repeat protein
WO2012149439A2 (en) * 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
CN104508129A (en) * 2012-06-28 2015-04-08 分子伴侣公司 Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) * 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
KR102236367B1 (en) * 2013-07-26 2021-04-05 삼성전자주식회사 Bispecific chimeric proteins with DARPins
ES2773317T3 (en) * 2013-11-05 2020-07-10 Allergan Inc Method of treating eye conditions with an anti-VEGF DARPin
IL276944B (en) * 2015-04-02 2022-07-01 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
WO2017210600A1 (en) * 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
CN109790206A (en) * 2016-09-22 2019-05-21 分子组合公司 Recombinant binding protein and application thereof

Also Published As

Publication number Publication date
IL288610A (en) 2022-02-01
CA3139164A1 (en) 2020-12-10
WO2020245173A1 (en) 2020-12-10
CN114269366A (en) 2022-04-01
AU2020286600A1 (en) 2021-12-23
EP3980045A1 (en) 2022-04-13
KR20220016942A (en) 2022-02-10
MX2021014601A (en) 2022-02-11
BR112021024231A2 (en) 2022-04-26
JP2022535415A (en) 2022-08-08
US20220242973A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
IL288610A (en) Recombinant fap binding proteins and their use
IL281783A (en) Sirpα binding proteins and methods of use thereof
IL278943A (en) Multi-specific binding proteins and improvements thereon
EP3623388A4 (en) Bispecific recombinant protein and use thereof
IL284633A (en) Polypeptides comprising modified il-2 polypeptides and uses thereof
IL287273A (en) Recombinant polyclonal proteins and methods of use thereof
IL287781A (en) Clec12a-binding polypeptides and uses thereof
EP3810172A4 (en) Heterodimeric proteins and uses thereof
IL284156A (en) Anti-ctla-4 binding proteins and methods of use thereof
IL276497A (en) Fibroblast binding agents and use thereof
IL284157A (en) Anti-pd-1 binding proteins and methods of use thereof
IL287782A (en) Cd33-binding polypeptides and uses thereof
ZA202100859B (en) Recombinant protein variants
ZA202101250B (en) Novel crispr-associated protein and use thereof
SG11202110400QA (en) Fusion protein and use thereof
ZA202101260B (en) Long-acting recombinant glp1-fc-cd47 protein, preparation method and use thereof
IL275593B (en) Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
SG11202100568WA (en) Il-17a binding peptides and medical uses thereof
EP4081241A4 (en) Regenerative polypeptides and uses thereof
IL304317A (en) Tgf-beta-rii binding proteins
EP3946451A4 (en) Fibroblast activation protein binding agents and use thereof
IL289145A (en) Il1rap binding proteins
IL291364A (en) Antigen binding proteins
EP3976630A4 (en) Actrii-binding proteins and uses thereof
IL287187A (en) Artificial recombinant chromosome and use thereof